Table 3

Changes from baseline to week 208 in mSASSS (employing linear extrapolation for missing data)

	Placebo→golimumab 50 mg*	Golimumab
	Placebo→golimumab 50 mg*	50 mg*	100 mg*
Patients in radiographic substudy, n	66	111	122
mSASSS change, by randomised group
Mean±SD	2.1±5.2	1.3±4.1	2.0±5.6
Median (IQR)	0.0 (0.0, 2.5)	0.0 (0.0, 2.2)	0.0 (0.0, 2.7)
p Value for 50 vs 100 mg		0.16
mSASSS change, by receipt of 50 mg vs 100 mg, n		177	122
Mean±SD	–	1.6±4.5	2.0±5.6
Median (IQR)	–	0.0 (0.0, 2.2)	0.0 (0.0, 2.7)
p Value for 50 vs 100 mg		0.25
mSASSS change in patients with baseline syndesmophytes,^† n	40	68	71
Mean±SD	3.6±6.2	2.1±5.0	2.9±6.5
Median (IQR)	1.9 (0.0, 5.9)	0.5 (−0.4, 4.0)	1.5 (0.0, 6.1)
mSASSS change in patients without baseline syndesmophytes,^† n	24	42	45
Mean±SD	−0.1±0.5	0.1±0.9	0.4±1.6
Median (IQR)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
mSASSS change in all patients with baseline syndesmophytes,^† n		All patients 179
Mean±SD		2.8±5.9
Median (IQR)		1.1 (0.0, 5.2)
mSASSS change in all patients without baseline syndesmophytes,^† n		All patients 111
Mean±SD		0.2±1.2
Median (IQR)		0.0 (0.0, 0.0)
p Value vs patients with baseline syndesmophytes		<0.0001
mSASSS change >2, n (%)
Proportions of patients by randomised treatment group	19 (28.8%)	29 (26.1%)	35 (28.7%)
Proportion of all patients		All patients 83/299 (27.8%)
Annual progression rate at week 208 (change in mSASSS per year), Mean±SD	0.5±1.3	0.4±1.7	0.5±1.4

*Patients in the placebo group started golimumab 50 mg at either week 16 (early escape) or week 24 (crossover) per protocol. Patients in the 50-mg group could escalate the golimumab dose to 100 mg at week 16 if they qualified for early escape. Patients in the 100-mg group continued to receive 100 mg regardless of early escape status.
†Defined as ≥1 level of spine with a score ≥2 (syndesmophytes) at baseline and a follow-up evaluation for ≥1 reader.
mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.